about
Aminosalicylates for induction of remission or response in Crohn's diseaseAminosalicylates for induction of remission or response in Crohn's diseaseMonocytes in inflammatory bowel disease: absolute monocyte counts.Monocytes in inflammatory bowel disease: phagocytosis and intracellular killing.Technetium-99m autologous phagocyte scanning: a new imaging technique for inflammatory bowel disease.Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease.Serum lysozyme levels in Crohn's disease and ulcerative colitis.Course and prognosis of Crohn's disease.Clq metabolism in ulcerative colitis and Crohn's diseaseInflammatory bowel disease: study of cell mediated cytotoxicity for isolated human colonic epithelial cells.Crohn's disease of the distal ileum.T lymphocyte subsets in inflammatory bowel disease: peripheral bloodInflammatory bowel disease associated circulating immune complexesAssessment of drug therapy in inflammatory bowel diseaseCirculating human leucocyte elastase in patients with inflammatory bowel diseaseDiffering acute phase responses in Crohn's disease and ulcerative colitis.Sensitization to epithelial antigens in chronic mucosal inflammatory disease. Characterization of human intestinal mucosa-derived mononuclear cells reactive with purified epithelial cell-associated components in vitro.Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease?T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans.Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease.An epidermilogical survey of Crohn's disease in Northern Ireland.IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis.Prognosis and management of Crohn's disease in the over-55 age group.Crohn's disease in Northern Ireland--a retrospective study of 440 cases.The protean manifestations of Crohn's disease.The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial.Variation in gut-homing CD27-negative lymphocytes in inflammatory colon disease.Drug therapy of inflammatory bowel disease.Assessment of disease severity and activity in inflammatory bowel disease.Motility of neutrophils and monocytes in Crohn's disease and ulcerative colitis.Complement inhibitors and immunoconglutinins in ulcerative colitis and Crohn's disease.In vitro model for the assessment of luminal factors on rectal mucosaAltered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation.Significance of serum complement levels in patients with gastrointestinal disease.Humoral immune system in inflammatory bowel disease: I. Complement levels.Toxic oxygen metabolite production by circulating phagocytic cells in inflammatory bowel disease.Serum and faecal lysozyme in inflammatory bowel disease.A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease.Treatment of Crohn's disease with an unrefined-carbohydrate, fibre-rich diet.
P2860
Q24235730-FE66E1C7-8B81-4344-9F79-F1FAB3CC076DQ26471183-A666D25C-7370-4DF3-AA2C-BA92140CB022Q33848357-AC119FA9-5902-4784-8DDD-FD6A1D987591Q33848363-5310C108-F239-4765-BDB5-4D8FCD91B494Q34287319-D5AE0D86-0D13-4737-B76E-1A53A38ABBCAQ34321127-20E4C6AE-586D-486B-8F2F-F5D9B62E0CA4Q34394229-038EFC24-8056-4C3D-85B9-C34E78E84680Q34471850-AC4DA87A-E94B-4749-A610-4C8D9897EA5AQ34472070-A85DBDB0-084B-46F2-AA4B-03DFA4EF5618Q34476061-D32379B0-F6F9-43DF-94E1-2D4D41DFEBB1Q34493320-2D3BC1E3-53B9-4335-9AD7-2020CCC54749Q34493826-068ACB08-E8DC-4F61-9962-85F089921973Q34496347-FF07C974-660A-4BD1-AD17-41A8654ECF57Q34496939-62A74F09-F624-4A73-AFBA-241569236B77Q34512251-0D10B4E0-B8E4-4BDD-B2F1-D9CEE90A312CQ34528237-25F014B1-7893-4110-A0E5-1103CB290ED0Q34529836-39EF8A38-A232-4782-9451-6F14C196A6C9Q34530829-225DA046-0E02-4694-A843-36C9AE105E05Q34609407-C36F3833-1CA8-47AE-BE13-4CF2B9F5440CQ35355393-DB417B6C-06C0-44B0-9A20-FB6A505CC430Q35364122-4A3210FF-58FA-4D90-B767-F428B0AC2071Q35779495-F453903D-F667-43AD-A3C9-284971F67620Q36663722-53183334-1217-4E93-99ED-2C83C4E932CAQ36727746-2DE2E0FC-BE36-4563-9DEC-22041E626F65Q36750253-5015645F-8B57-492F-8DC3-D388393160ADQ38080770-5E980C08-725B-4337-AAA5-05C246F46760Q39186837-CC8D3208-8626-4027-8CE7-693CAECB4D99Q39240437-3DFE3182-5F33-47AD-B294-006E95131AB2Q40090889-11A8361E-8E04-408F-9193-ED3E471675EEQ40874249-5C0F794C-AC3F-4D61-BBDF-9694D4F3C243Q41605450-0D9D467D-1FD2-4B88-BDBE-97BD6AED69FBQ41916660-308A135A-0F8D-4C33-8C5F-384335F16AAAQ42011312-31E704BC-BBA1-497D-B050-146B9F42B1E2Q42580894-C6E52355-9AEE-4A36-8CB6-9100419F3E4CQ42851323-B6A5E26B-F154-4D19-9FE2-76B9D0E8B73AQ43218497-F1F8F02D-9F6E-4112-9557-D7325703DCF9Q43219054-6098A833-605A-4F9A-BBDC-7F4A208B2AD2Q43249689-FC65FB14-1BF3-4FC0-9DF8-D8319804C6C6Q46977299-E6C6575F-9E99-48C1-93B7-014A1753F907Q55456155-BDB40FF5-39FD-4962-A967-2023284B50E5
P2860
description
1974 nî lūn-bûn
@nan
1974 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1974 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1974年の論文
@ja
1974年論文
@yue
1974年論文
@zh-hant
1974年論文
@zh-hk
1974年論文
@zh-mo
1974年論文
@zh-tw
1974年论文
@wuu
name
Short-term course and prognosis of Crohn's disease
@ast
Short-term course and prognosis of Crohn's disease
@en
Short-term course and prognosis of Crohn's disease
@nl
type
label
Short-term course and prognosis of Crohn's disease
@ast
Short-term course and prognosis of Crohn's disease
@en
Short-term course and prognosis of Crohn's disease
@nl
prefLabel
Short-term course and prognosis of Crohn's disease
@ast
Short-term course and prognosis of Crohn's disease
@en
Short-term course and prognosis of Crohn's disease
@nl
P2093
P2860
P356
P1433
P1476
Short-term course and prognosis of Crohn's disease
@en
P2093
De Dombal FT
Goligher JC
P2860
P304
P356
10.1136/GUT.15.6.435
P407
P577
1974-06-01T00:00:00Z